State-of-the-art pharmacotherapy for diabetic neuropathy.


INTRODUCTION:The global epidemic of diabetes has led to an epidemic of diabetes complications. Diabetic neuropathy is the most common microvascular complication, of which diabetic peripheral neuropathy (DPN) and autonomic neuropathy (AN) are the most prevalent, affecting ~50% of patients. DPN results in pain with a poor quality of life and a loss of sensation with an increased risk of foot ulceration. Autonomic neuropathy can cause significant morbidity in a minority and is associated with increased mortality. The cornerstone of treatment to prevent or limit the progression of DPN/AN is multifactorial risk factor modification including treatment of glycemia, lipids and blood pressure. Whilst, there are no FDA-approved disease-modifying therapies, there are a number of therapies to relieve symptoms in DPN and AN. AREAS COVERED:The authors discuss current approved therapies for painful diabetic neuropathy and autonomic neuropathy. They also address the potential role of improving risk factors to limit the development and progression of diabetic neuropathy and new pathogenetic and pain-relieving treatments. EXPERT OPINION:The FDA-approved Pregabalin and Duloxetine over 25 years ago and Tapentadol, 6 years ago for painful diabetic neuropathy. There are currently no FDA-approved disease-modifying treatments for diabetic neuropathy which has been attributed to inappropriate models of the disease with limited translational capacity and major limitations of trial designs and endpoints in clinical trials.


Azmi S,Alam U,Burgess J,Malik RA




Has Abstract


2021-01-01 00:00:00












  • A review of the clinical efficacy and tolerability of almotriptan in acute migraine.

    abstract::Almotriptan is a serotonin (5-hydroxytryptamine, 5HT)(1B/1D)-receptor agonist approved for the acute treatment of migraine. In 3500 acute migraine patients enrolled in short-term trials and 1500 patients in long-term open-label trials, almotriptan 12.5 mg was effective and well-tolerated. Almotriptan maintains a consi...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审


    authors: Dodick DW

    更新日期:2003-07-01 00:00:00

  • Clinical review of Clostridium difficile infection: an update on treatment and prevention.

    abstract:INTRODUCTION:Clostridium difficile infection (CDI) has become a significant healthcare-associated infection and is strongly associated with antibiotic use. Practice guidelines have recently been revised incorporating updated recommendations for diagnosis, treatment, and prevention. AREAS COVERED:This review discusses ...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审


    authors: Daniels LM,Kufel WD

    更新日期:2018-11-01 00:00:00

  • Pediatric status epilepticus: improved management with new drug therapies?

    abstract:INTRODUCTION:Status Epilepticus (SE) is the most common neurological emergency of childhood. It requires prompt administration of appropriately selected anti-seizure medications. Areas covered: Following a distinction between estabilished and emergent drugs, we present pharmacological treatment options and their clinic...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审


    authors: Verrotti A,Ambrosi M,Pavone P,Striano P

    更新日期:2017-06-01 00:00:00

  • Efficacy of elagolix in the treatment of endometriosis.

    abstract:INTRODUCTION:Much research has gone into developing medications that can be used to alleviate endometriosis-associated symptoms. In addition to already established medications, a new GnRH antagonist, elagolix, is in development. The novelty of this drug compared to other GnRH antagonists, is its nonpeptide structure, a...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审


    authors: Perricos A,Wenzl R

    更新日期:2017-09-01 00:00:00

  • Approved and emerging PI3K inhibitors for the treatment of chronic lymphocytic leukemia and non-Hodgkin lymphoma.

    abstract:INTRODUCTION:PI3K inhibition with idelalisib (at that time CAL-101) was at the forefront of the development of molecularly targeted therapies in Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Leukemia (SLL) and follicular lymphoma. However, after initial approval, subsequent trials identified specific immune-medi...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审


    authors: Kienle DL,Stilgenbauer S

    更新日期:2020-06-01 00:00:00

  • The therapeutic management of differentiated thyroid cancer.

    abstract:BACKGROUND:The management of thyroid cancer is difficult because the tumors comprise a wide range of biologic behaviors, from small papillary thyroid microcarcinomas that pose little or no threat to survival for the patient, to anaplastic thyroid cancers that are arguably the most lethal tumor. Although it may be diffi...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审


    authors: Sipos JA,Mazzaferri EL

    更新日期:2008-10-01 00:00:00

  • Etravirine: the renaissance of non-nucleoside reverse transcriptase inhibitors.

    abstract:BACKGROUND:Etravirine is the first non-nucleoside reverse transcriptase inhibitor (NNRTI) to be active against human immunodeficiency virus with NNRTI mutations. OBJECTIVE:To understand the unique features of etravirine and to evaluate its safety, efficacy, and optimal use. METHODS:The structure and the mechanism of ...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章


    authors: Jayaweera DT,Espinoza L,Castro J

    更新日期:2008-12-01 00:00:00

  • Exemestane in postmenopausal women with early or advanced breast cancer: a review.

    abstract:IMPORTANCE OF THE FIELD:Inhibition of the aromatase enzyme in postmenopausal women reduces levels of estrogens, which is of therapeutic value in hormone-sensitive breast cancer. Exemestane is a third-generation steroidal irreversible inactivator of the aromatase enzyme used in early and advanced breast cancer for the t...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审


    authors: Bertelli G,Gangadhara S

    更新日期:2010-08-01 00:00:00

  • The changing pattern of adherence to antiretroviral therapy assessed at two time points, 12 months apart, in a cohort of HIV-infected children.

    abstract:OBJECTIVE:In a previous multicentre study including 129 HIV-infected children, non-adherence to antiretroviral therapy was detected in 16% of patients and was mainly related to psychosocial rather than clinical or demographic features. The aim of this study was to explore the evolving pattern of adherence and its deter...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,多中心研究


    authors: Giannattasio A,Albano F,Giacomet V,Guarino A

    更新日期:2009-12-01 00:00:00

  • Pharmacotherapy for knee osteoarthritis: current and emerging therapies.

    abstract:INTRODUCTION:Osteoarthritis (OA) is the leading cause of pain, loss of function and disability in the elderly, with the knee being the most impactful joint affected. Currently, there is still no 'cure' in OA treatment. AREAS COVERED:The authors review the current and emerging therapies for knee OA including traditiona...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审


    authors: Cao P,Li Y,Tang Y,Ding C,Hunter DJ

    更新日期:2020-05-01 00:00:00

  • Pharmacotherapy for the prevention of malaria in pregnant women: currently available drugs and challenges.

    abstract:INTRODUCTION:Malaria in pregnancy continues to be a significant public health burden globally, with over 100 million women at risk each year. Sulfadoxine-pyrimethamine (SP) is the only antimalarial recommended for intermittent preventive therapy in pregnancy (IPTp) but increasing parasite resistance threatens its viabi...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审


    authors: Moore BR,Davis TME

    更新日期:2018-11-01 00:00:00

  • Chemoradiotherapy for lung cancer.

    abstract::Chemoradiotherapy is a standard treatment for both unresectable locally advanced non-small cell lung cancer and limited-stage small cell lung cancer. Cisplatin-based chemotherapy with concurrent thoracic radiotherapy yields a 5-year survival rate of approximately 15% for patients with unresectable locally advanced non...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审


    authors: Ohe Y

    更新日期:2005-12-01 00:00:00

  • New phosphodiesterase inhibitors in the treatment of erectile dysfunction.

    abstract::Sildenafil revolutionised the treatment of erectile dysfunction (ED) on its introduction in 1998. Not only is it effective, but is, perhaps even more importantly, an extremely acceptable manner in which to treat ED (i.e., oral pharmacotherapy), compared to the other treatments that were available at that time (e.g., i...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审


    authors: Anderson PC,Gommersall L,Hayne D,Arya M,Patel HR

    更新日期:2004-11-01 00:00:00

  • Flecainide acetate for the treatment of atrial and ventricular arrhythmias.

    abstract:INTRODUCTION:Flecainide is a class Ic antiarrhythmic agent available in Europe since 1982. The clinical development program of flecainide provided good data on its antiarrhythmic effect for the prevention of ventricular and supraventricular arrhythmias. The Cardiac Arrhythmia Suppression Trial (CAST), conducted to test...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审


    authors: Apostolakis S,Oeff M,Tebbe U,Fabritz L,Breithardt G,Kirchhof P

    更新日期:2013-02-01 00:00:00

  • Ziprasidone for maintenance treatment of bipolar I disorder in adults.

    abstract:INTRODUCTION:Antipsychotic drugs are increasingly used in the maintenance treatment of bipolar disorder. This review addresses the evidence supporting the use of one of these medications for this indication in order to place available data in perspective for the clinician. AREAS COVERED:The approval of ziprasidone for...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章


    authors: Dubovsky SL,Dubovsky AN

    更新日期:2011-04-01 00:00:00

  • Treatment of classical Hodgkin's lymphoma in children and adolescents.

    abstract:INTRODUCTION:The treatment of classical Hodgkin lymphoma (cHL) in children is a story of success. Nowadays, more than 90% of patients are cured and overall survival is nearly 100% at 5 years. Efforts have been made to avoid related effects of therapies; therefore, children are treated using different chemotherapy schem...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审


    authors: Gómez-Almaguer D,González-Llano O,Jiménez-Antolinez V,Gómez-De León A

    更新日期:2019-07-01 00:00:00

  • Pharmacological treatment for uterine leiomyosarcomas.

    abstract:INTRODUCTION:Pharmacological treatment plays a major role in the management of advanced, persistent or recurrent uterine leiomyosarcoma (LMS), whereas its usefulness in the adjuvant setting is still debated. A thorough literature search was undertaken using the Pubmed databases. Systematic reviews and controlled trials...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审


    authors: Gadducci A,Guerrieri ME

    更新日期:2015-02-01 00:00:00

  • Pharmacokinetic profile of a new formulation of injection diclofenac designed for intradeltoid use.

    abstract:OBJECTIVE:Injection diclofenac sodium available at present as a 3-ml formulation is administered intragluteally. Standard needles may not reach the gluteus maximus muscle in many cases, especially in obese patients. Alternative sites like the deltoid have been suggested to be more suitable for these patients. Diclofena...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章


    authors: Ojha A,Shep D,Nivsarkar M,Patel S,Jaiswal V,Padh H

    更新日期:2009-03-01 00:00:00

  • Quetiapine for the treatment of acute bipolar mania, mixed episodes and maintenance therapy.

    abstract:INTRODUCTION:Bipolar disorder is characterized by mood instability, which can be challenging to manage. First-line pharmacological approaches usually involve lithium, anticonvulsants and antipsychotics. Over the past fifteen years, several second-generation antipsychotics have demonstrated benefits for various phases o...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章


    authors: Janicak PG,Rado JT

    更新日期:2012-08-01 00:00:00

  • Ceftazidime for respiratory infections.

    abstract:INTRODUCTION:Ceftazidime is a third-generation cephalosporin that has activity against Gram-negative bacilli, including Pseudomonas aeruginosa. The increasing prevalence of antimicrobial resistance and the limited number of antimicrobial agents in development have necessitated a review of the current status of treatmen...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审


    authors: Choi SH,Koh Y

    更新日期:2012-10-01 00:00:00

  • An overview of intravenous amisulpride as a new therapeutic option for the prophylaxis and treatment of postoperative nausea and vomiting.

    abstract::Introduction: Current therapies of postoperative nausea and vomiting (PONV) are based on a combination of antiemetics from different pharmacological classes. Dopamine receptor antagonists are one of the cornerstones of such multimodal antiemetic approach, with droperidol being the best studied representative of this g...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审


    authors: Smyla N,Koch T,Eberhart LH,Gehling M

    更新日期:2020-04-01 00:00:00

  • Efficacy of colestilan in the treatment of hyperphosphataemia in renal disease patients.

    abstract:INTRODUCTION:Hyperphosphataemia is common in chronic kidney disease (CKD), particularly in the late stages and is associated with secondary hyperparathyroidism, abnormal bone mineralisation and increased cardiovascular morbidity/mortality. At present, there is a range of phosphate binders designed to keep serum phospha...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审


    authors: Locatelli F,Dimkovic N,Spasovski G

    更新日期:2014-07-01 00:00:00

  • Efficacy of indacaterol as a single therapy versus salmeterol/fluticasone therapy in patients with milder chronic obstructive pulmonary disease.

    abstract:INTRODUCTION:In non-exacerbation chronic obstructive pulmonary disease (COPD) with mild lung function impairment, single bronchodilator therapy might be as effective as combined inhaled corticosteroid/bronchodilator therapy, whereas the risk of pneumonia associated with the latter would be practically absent. AREAS CO...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 评论,杂志文章


    authors: Ruxandra U,Antoniu SA,Mihaltan F,Boisteanu D

    更新日期:2015-01-01 00:00:00

  • Fesoterodine: a novel muscarinic receptor antagonist for the treatment of overactive bladder syndrome.

    abstract:BACKGROUND:Fesoterodine is a newly approved drug for the treatment of overactive bladder syndrome. OBJECTIVE:The aim of this study was to review the preclinical and clinical data on fesoterodine. METHODS:The study involved a search of the Medline database and the proceedings volumes of urological congresses. RESULTS...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审


    authors: Michel MC

    更新日期:2008-07-01 00:00:00

  • Advances in orally administered pharmacotherapy for the treatment of migraine.

    abstract:INTRODUCTION:Migraine is a common and highly disabling neurological disorder whose acute treatment remains problematic and unsatisfactory in a high percentage of cases. Consequently, there remains a need for new symptomatic therapies that can be easily handled by patients (i.e. by oral administration). AREAS COVERED:T...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审


    authors: Martelletti P,Giamberardino MA

    更新日期:2019-02-01 00:00:00

  • An in-depth review of chemical angiogenesis inhibitors for treating hepatocellular carcinoma.

    abstract:INTRODUCTION:Hepatocellular carcinoma (HCC) is a frequent and severe complication of cirrhosis. Most HCC patients initially present with or progress to advanced stage disease and require systemic treatment. As hypervascularization is a major characteristic of HCC, antiangiogenic drugs have been tested. Areas covered: I...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审


    authors: Raoul JL,Gilabert M,Adhoute X,Edeline J

    更新日期:2017-10-01 00:00:00

  • Outpatient management of chronic heart failure.

    abstract:INTRODUCTION:Heart failure (HF) treatment attracts a share of intensive research because of its poor HF prognosis. In the past decades, the prognosis of HF has improved considerably, mainly as a consequence of the progress that has been made in the pharmacological management of HF. AREAS COVERED:This article reviews t...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审


    authors: Kaldara E,Sanoudou D,Adamopoulos S,Nanas JN

    更新日期:2015-01-01 00:00:00

  • Treatment of bacterial vaginosis: what we have and what we miss.

    abstract:INTRODUCTION:The disturbing, foul-smelling discharge of bacterial vaginosis (BV) is a nuisance to women. Treatment possibilities for BV are limited and only achieve complete cure in 65 to 85% of cases. In most women, the condition relapses within weeks to months after treatment. AREAS COVERED:In search of new therapeu...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审


    authors: Donders GG,Zodzika J,Rezeberga D

    更新日期:2014-04-01 00:00:00

  • Assessment and management of acute pain in high-risk neonates.

    abstract::Neonates in the neonatal intensive care unit experience hundreds of painful procedures at a time of rapid neurological development. Although the immediate responses to pain may be protective, the potential long-term effects of early and under-treated pain are concerning. As pain assessment is the first step in the pro...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审


    authors: Gibbins S,Stevens B,Asztalos E

    更新日期:2003-04-01 00:00:00

  • Neuraminidase inhibitors as a strategy for influenza treatment: pros, cons and future perspectives.

    abstract::Introduction: Influenza represents a major public health threat worldwide. Implementation of good personal health and hygiene habits, together with vaccination, is the most effective tools to reduce influenza burden both in community and in healthcare setting. However, achieving adequate vaccination rates is challengi...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审


    authors: Bassetti M,Castaldo N,Carnelutti A

    更新日期:2019-10-01 00:00:00